A single tertiary center outcomes on cannulation strategies and extracorporeal membrane oxygenation in the treatment of respiratory failure during COVID-19 infection
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2021Yazar
Ulukan, Mustafa ÖzerKarakaya, Atalay
Yıldız, Yahya
Öztaş, Didem Melis
Kamilçelebi, Nurdan
Özdemir, Servet
Uğurlucan, Murat
Erkanlı, Korhan
Üst veri
Tüm öğe kaydını gösterKünye
Ulukan, M. Ö., Karakaya, A., Yıldız, Y., Öztaş, D. M., Kamilçelebi, N., Özdemir, S. ... Erkanlı, K. (2021). A single tertiary center outcomes on cannulation strategies and extracorporeal membrane oxygenation in the treatment of respiratory failure during COVID-19 infection. The Medical Bulletin of Haseki, 59, 25-30. https://dx.doi.org/10.4274/haseki.galenos.2021.7144Özet
Aim: Extracorporeal membrane oxygenation (ECMO) is an important option for the management of severe acute respiratory distress syndrome (ARDS) in Coronavirus disease-2019 (COVID-19) cases. We aimed to present our experiences of ECMO in patients with respiratory failure secondary to COVID-19. Methods: Data of 22 consecutive COVID-19 patients with severe respiratory failure whom were supported with ECMO were collected from computer-based hospital software retrospectively. Patients were treated in a single medical center between April 23, 2020 and February 14, 2021. Patients were analyzed from the points of laboratory and inflammatory markers, ventilation and ECMO features. Results: The ages of patients were between 30 and 69 years (mean age: 56.3±10.63). All patients were under maximum ventilator support, with the prone position. All patients had elevated levels of inflammatory indicators as D-dimer and ferritin. The mean level of ferritin was 1, 564±1, 611 ng/mL. D-dimer value was maximum 10.000 mg/mL (mean: 5, 215±3, 104), CRP increased to 177 mg/L (mean: 159±71). Percent of lymphocytes decreased as low as 2% (mean: 4.16±2.10). The mean duration of veno-arterial (VA) ECMO was 1.6±0.94 days whereas, for veno-venous (VV) ECMO, it was 10.05±5 days. VA ECMO was decided due to cardiovascular collapse. Four patients with VA ECMO survived a maximum of 3 days. Four of (22.22%) of 18 VV ECMO supported patient’s blood gas values were at normal ranges, 3 of them needed tracheostomy, and all of could be discharged from the hospital. Conclusion: Although, ECMO support for severe respiratory failure patients with COVID-19 is more challenging than regular ECMO applications, especially VV ECMO usage should be reminded as a remedy.
Scopus Q Kategorisi
Q4Kaynak
The Medical Bulletin of HasekiCilt
59Bağlantı
https://dx.doi.org/10.4274/haseki.galenos.2021.7144https://hdl.handle.net/20.500.12511/7813
Koleksiyonlar
- Makale Koleksiyonu [3651]
- Scopus İndeksli Yayınlar Koleksiyonu [6285]
- TR-Dizin İndeksli Yayınlar Koleksiyonu [2175]